SG10201605325TA - P2x4 receptor antagonist - Google Patents
P2x4 receptor antagonistInfo
- Publication number
- SG10201605325TA SG10201605325TA SG10201605325TA SG10201605325TA SG10201605325TA SG 10201605325T A SG10201605325T A SG 10201605325TA SG 10201605325T A SG10201605325T A SG 10201605325TA SG 10201605325T A SG10201605325T A SG 10201605325TA SG 10201605325T A SG10201605325T A SG 10201605325TA
- Authority
- SG
- Singapore
- Prior art keywords
- receptor antagonist
- antagonist
- receptor
- Prior art date
Links
- 102100037601 P2X purinoceptor 4 Human genes 0.000 title 1
- 101710189967 P2X purinoceptor 4 Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012005343 | 2012-01-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201605325TA true SG10201605325TA (en) | 2016-08-30 |
Family
ID=48781550
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201404030YA SG11201404030YA (en) | 2012-01-13 | 2013-01-10 | P2x4 receptor antagonist |
| SG10201605325TA SG10201605325TA (en) | 2012-01-13 | 2013-01-10 | P2x4 receptor antagonist |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201404030YA SG11201404030YA (en) | 2012-01-13 | 2013-01-10 | P2x4 receptor antagonist |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US9382236B2 (en) |
| EP (1) | EP2803662B1 (en) |
| JP (1) | JP6207399B2 (en) |
| KR (2) | KR102140746B1 (en) |
| CN (4) | CN110483423A (en) |
| AU (1) | AU2013208536B2 (en) |
| CA (1) | CA2861024C (en) |
| DK (1) | DK2803662T3 (en) |
| ES (1) | ES2626036T3 (en) |
| IL (1) | IL233592B (en) |
| NZ (1) | NZ627878A (en) |
| PL (1) | PL2803662T3 (en) |
| PT (1) | PT2803662T (en) |
| SG (2) | SG11201404030YA (en) |
| WO (1) | WO2013105608A1 (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2626036T3 (en) | 2012-01-13 | 2017-07-21 | Nippon Chemiphar Co., Ltd. | P2X4 receptor antagonist |
| JP6357475B2 (en) | 2013-07-12 | 2018-07-11 | 日本ケミファ株式会社 | P2X4 receptor antagonist |
| EP3564217B1 (en) | 2013-07-12 | 2021-01-27 | Nippon Chemiphar Co., Ltd. | P2x4 receptor antagonist |
| WO2015088565A1 (en) * | 2013-12-13 | 2015-06-18 | Sunovion Pharmaceuticals Inc. | P2x4 receptor modulating compounds and methods of use thereof |
| EP3274336A4 (en) | 2015-03-24 | 2018-11-14 | Piramal Enterprises Limited | An improved process for the preparation of clobazam and its intermediate |
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| PL3426245T3 (en) | 2016-03-07 | 2023-05-22 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| KR102535907B1 (en) * | 2016-04-28 | 2023-05-23 | 닛뽕 케미파 가부시키가이샤 | Medications for the treatment of multiple sclerosis |
| CA3022793A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Aromatic sulfonamide derivatives |
| WO2018104307A1 (en) | 2016-12-09 | 2018-06-14 | Bayer Pharma Aktiengesellschaft | Aromatic sulfonamide derivatives and their use as anatagon i sts or negative allosteric modulators of p2x4 |
| WO2018104305A1 (en) | 2016-12-09 | 2018-06-14 | Bayer Pharma Aktiengesellschaft | Field of application of the invention |
| WO2018210729A1 (en) | 2017-05-18 | 2018-11-22 | Bayer Pharma Aktiengesellschaft | Aromatic sulfonamide derivatives as antagonists or negative allosteric modulators of p2x4 receptor |
| EP3675637A4 (en) | 2017-08-28 | 2021-05-19 | Enanta Pharmaceuticals, Inc. | ANTIVIRAL AGENTS AGAINST HEPATITIS B |
| WO2019143902A2 (en) | 2018-01-22 | 2019-07-25 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| CA3093651A1 (en) | 2018-03-14 | 2019-09-19 | Nippon Chemiphar Co., Ltd. | Medicament for treating cough |
| EP3848051A4 (en) * | 2018-09-03 | 2022-06-08 | Nippon Chemiphar Co., Ltd. | Medicine for diabetic peripheral neuropathy |
| AR116474A1 (en) | 2018-09-21 | 2021-05-12 | Enanta Pharm Inc | 6,7-DIHYDRO-2H-BENZOFUR [2,3-a] QUINOLIZIN-3-CARBOXYL ACID DERIVATIVES AS ANTIVIRAL AGENTS FOR THE TREATMENT OR PREVENTION OF HBV INFECTION |
| EP3883570A4 (en) | 2018-11-21 | 2022-07-13 | Enanta Pharmaceuticals, Inc. | FUNCTIONALIZED HETEROCYCLES USEFUL AS ANTIVIRAL AGENTS |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| JP2023509452A (en) | 2020-01-03 | 2023-03-08 | バーグ エルエルシー | Polycyclic Amides as UBE2K Modulators to Treat Cancer |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| WO2021198745A1 (en) * | 2020-03-30 | 2021-10-07 | ルーカ アントニオーリ | Drug for prevention or treatment of irritable bowel syndrome or inflammatory bowel disease |
| EP4171744A1 (en) * | 2020-06-30 | 2023-05-03 | Bayer Aktiengesellschaft | Use of n-phenylacetamides having p2x4 receptor antagonistic activity for treating certain ocular disorders |
| KR20230031307A (en) | 2020-06-30 | 2023-03-07 | 바이엘 악티엔게젤샤프트 | Substituted N-phenylacetamides with P2X4 receptor antagonistic activity |
| WO2022030428A1 (en) | 2020-08-03 | 2022-02-10 | 日本ケミファ株式会社 | Pharmaceutical composition for preventing, suppressing, or treating symptoms associated with allergic reaction |
| WO2022049253A1 (en) | 2020-09-07 | 2022-03-10 | Bayer Aktiengesellschaft | Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators |
| MX2023014819A (en) | 2021-06-14 | 2024-03-21 | Scorpion Therapeutics Inc | Urea derivatives which can be used to treat cancer. |
| IT202100025124A1 (en) | 2021-09-30 | 2023-03-30 | Univ Degli Studi Di Firenze | MEDICINAL PRODUCT FOR USE IN THE PREVENTION OR TREATMENT OF NOCICEPTIVE AND/OR VISCERAL PAIN |
| EP4410310A4 (en) * | 2021-09-30 | 2025-10-22 | Nippon Chemiphar Co | Prophylactic or therapeutic agent for respiratory diseases |
| JP2025041993A (en) * | 2022-02-17 | 2025-03-27 | 国立大学法人鳥取大学 | Preventive or therapeutic agent for endometriosis or adenomyosis |
| CA3246964A1 (en) | 2022-03-31 | 2025-07-09 | Nippon Chemiphar Co | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with pseudo-allergic reaction |
| TW202448478A (en) * | 2023-02-24 | 2024-12-16 | 日商日本化美化股份有限公司 | Solid dispersion of compound having p2x4 receptor antagonist activity |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5534960Y2 (en) | 1977-01-31 | 1980-08-18 | ||
| JPS53111093A (en) * | 1977-03-07 | 1978-09-28 | Takeda Chem Ind Ltd | Imidazo(1,5-d)(1,4)benzodiazepin derivative and its preparation |
| JPH02304437A (en) * | 1989-05-19 | 1990-12-18 | Konica Corp | Novel photographic coupler |
| EP0756602B1 (en) * | 1994-04-14 | 1999-06-30 | Glaxo Wellcome Inc. | Cck or gastrin modulating 5-heterocyclic-1,5-benzodiazepines |
| PE27497A1 (en) | 1994-04-15 | 1997-08-07 | Glaxo Inc | DERIVATIVES OF 1,5 BENZODIAZEPINA |
| SE0104250D0 (en) | 2001-12-14 | 2001-12-14 | Astrazeneca Ab | Heterocyclic compounds |
| WO2004041258A2 (en) * | 2002-10-30 | 2004-05-21 | Neuro3D | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
| DE10312969A1 (en) | 2003-03-24 | 2004-10-07 | Bayer Healthcare Ag | Benzofuro-1,4-diazepin-2-one derivatives |
| US20050074819A1 (en) | 2003-10-01 | 2005-04-07 | Japan Health Sciences Foundation | Screening method of drug for treatment of neuropathic pain |
| KR100512749B1 (en) | 2004-01-14 | 2005-09-07 | 삼성전자주식회사 | Monitor |
| US20100298285A1 (en) | 2006-03-16 | 2010-11-25 | Kelly Michael G | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof |
| EP2058304A4 (en) * | 2006-08-25 | 2012-10-10 | Nippon Chemiphar Co | P2x4 receptor antagonist |
| SI2129396T1 (en) | 2007-02-16 | 2013-12-31 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
| JP2012087053A (en) | 2009-02-03 | 2012-05-10 | Nippon Chemiphar Co Ltd | Diazepinedione derivative |
| ES2432265T3 (en) * | 2009-02-16 | 2013-12-02 | Nippon Chemiphar Co., Ltd. | Diazepindione derivative |
| CA2807354C (en) * | 2010-07-13 | 2018-06-05 | Nippon Chemiphar Co., Ltd. | P2x4 receptor antagonist |
| JP2013209292A (en) * | 2010-07-23 | 2013-10-10 | Nippon Chemiphar Co Ltd | P2x4 receptor antagonist |
| US20140163013A1 (en) * | 2011-05-25 | 2014-06-12 | Nippon Chemiphar Co., Ltd. | Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome |
| ES2626036T3 (en) | 2012-01-13 | 2017-07-21 | Nippon Chemiphar Co., Ltd. | P2X4 receptor antagonist |
-
2013
- 2013-01-10 ES ES13736295.0T patent/ES2626036T3/en active Active
- 2013-01-10 KR KR1020207007764A patent/KR102140746B1/en active Active
- 2013-01-10 WO PCT/JP2013/050320 patent/WO2013105608A1/en not_active Ceased
- 2013-01-10 CN CN201910768337.XA patent/CN110483423A/en active Pending
- 2013-01-10 CN CN201810753396.5A patent/CN108863959B/en active Active
- 2013-01-10 CN CN201380005473.4A patent/CN104066724B/en active Active
- 2013-01-10 DK DK13736295.0T patent/DK2803662T3/en active
- 2013-01-10 AU AU2013208536A patent/AU2013208536B2/en active Active
- 2013-01-10 PL PL13736295T patent/PL2803662T3/en unknown
- 2013-01-10 EP EP13736295.0A patent/EP2803662B1/en active Active
- 2013-01-10 PT PT137362950T patent/PT2803662T/en unknown
- 2013-01-10 SG SG11201404030YA patent/SG11201404030YA/en unknown
- 2013-01-10 JP JP2013553310A patent/JP6207399B2/en active Active
- 2013-01-10 KR KR1020147022599A patent/KR102092147B1/en active Active
- 2013-01-10 CN CN202010213899.0A patent/CN111333588A/en active Pending
- 2013-01-10 US US14/371,868 patent/US9382236B2/en active Active
- 2013-01-10 CA CA2861024A patent/CA2861024C/en active Active
- 2013-01-10 SG SG10201605325TA patent/SG10201605325TA/en unknown
- 2013-01-10 NZ NZ627878A patent/NZ627878A/en unknown
-
2014
- 2014-07-10 IL IL233592A patent/IL233592B/en active IP Right Grant
-
2016
- 2016-06-08 US US15/176,857 patent/US9969700B2/en active Active
-
2018
- 2018-03-16 US US15/923,685 patent/US10633349B2/en active Active
-
2020
- 2020-03-23 US US16/826,877 patent/US11434207B2/en active Active
-
2022
- 2022-07-22 US US17/871,201 patent/US12116351B2/en active Active
-
2024
- 2024-08-28 US US18/817,846 patent/US20240417379A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL233592A0 (en) | P2x4 receptor antagonist | |
| GB201213700D0 (en) | Receptor antagnists II | |
| PT2927224T (en) | Receptor antagonists | |
| IL238974A0 (en) | Cxcr7 antagonists | |
| EP3020717A4 (en) | P2x4 receptor antagonist | |
| ZA201500781B (en) | 5-ht3 receptor antagonists | |
| HUE039607T2 (en) | Progesterone antagonists | |
| ZA201305576B (en) | Trpm8 receptor antagonists | |
| IL232503A (en) | 2h-indazoles as ep2 receptor antagonists | |
| EP2617717A4 (en) | P2x4 receptor antagonist | |
| ZA201408172B (en) | V1a receptor agonists | |
| ZA201500220B (en) | Novel cholecystokinin receptor ligands | |
| GB201223053D0 (en) | Receptor | |
| GB2504611B (en) | Fastened Structure | |
| GB201213699D0 (en) | Receptor antagonists II | |
| GB201213698D0 (en) | Receptor antagonists II | |
| IL230334A0 (en) | Nicotinic receptor non-competitive antagonists | |
| PL2800497T3 (en) | Lifting-recliner seating unit | |
| GB201210169D0 (en) | Seating |